Performing a Methacholine Challenge Test

Similar documents
Taking the Provocholine

GETTING STARTED WITH MANNITOL CHALLENGE TESTING. Rick Ballard, RRT, RPFT Applications/Education Specialist MGC Diagnostics

I. Subject: Continuous Aerosolization of Bronchodilators

ADASUVE (LOXAPINE) INHALATION POWDER. EDUCATION PROGRAM for HEALTHCARE PROFESSIONALS

Bronchial Provocation

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

Content Indica c tion Lung v olumes e & Lung Indica c tions i n c paci c ties

Version PACKAGE LEAFLET

Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges

SUMMARY OF PRODUCT CHARACTERISTICS

Spirometry and Flow Volume Measurements

Pulmonary Function Technologists (PFT) Detailed Content Outline

Lecture Notes. Chapter 3: Asthma

I. Subject: Medication Delivery by Metered Dose Inhaler (MDI)

Credential Maintenance Program

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?

NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

A COPD medication delivery device option: an overview of the NEOHALER

Independent Health Facilities

Portage Health Cardiopulmonary Policy. Cardiopulmonary. To provide guidelines for process and procedure with pulmonary function tests.

Pulmonary Function Tests. Mohammad Babai M.D Occupational Medicine Specialist

Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).

Biology 236 Spring 2002 Campos/Wurdak/Fahey Laboratory 4. Cardiovascular and Respiratory Adjustments to Stationary Bicycle Exercise.

Spirometry: Introduction

Pulmonary function response to EDTA, an additive in nebulized bronchodilators

SPIROMETRY. Marijke Currie (CRFS) Care Medical Ltd Phone: Copyright CARE Medical ltd

Exercise-Induced Bronchospasm. Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute

PRODUCT MONOGRAPH. PROVOCHOLINE methacholine chloride powder USP 100 mg, 160 mg, 320 mg, 1280 mg and 1600 mg

Objectives. Pulmonary Assessment 12/13/2017

PULMONARY FUNCTION TESTING. By: Gh. Pouryaghoub. MD Center for Research on Occupational Diseases (CROD) Tehran University of Medical Sciences (TUMS)

CPT (Current Procedural Terminology) and Drug Coding Guidance

PULMONARY FUNCTION TESTS

Beta 2 adrenoceptor agonists and the Olympic Games in Athens

MSRC AIR Course Karla Stoermer Grossman, MSA, BSN, RN, AE-C

This is a cross-sectional analysis of the National Health and Nutrition Examination

Using an Inhaler and Nebulizer

ARIDOL (mannitol inhalation powder) Full Prescribing Information and Test Kit Instructions. Bronchial Challenge Test Kit

NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS

6- Lung Volumes and Pulmonary Function Tests

Office Spirometry Guide

Spirometry Training Courses. Spirometry for. Thoracic Society of Australia and New Zealand. June Developed in partnership with

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016

Clinical Variables Are Poor Selection Criteria for the Use of Methacholine Bronchoprovocation in Symptomatic Subjects

UNIT TWO: OVERVIEW OF SPIROMETRY. A. Definition of Spirometry

Advanced Coding Allergy & Pulmonary Procedural Coding

Adenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma

Predictors of obstructive lung disease among seafood processing workers along the West Coast of the Western Cape Province

#7 - Respiratory System

LUNG FUNCTION TESTING: SPIROMETRY AND MORE

University of Groningen. Transdermal delivery of anticholinergic bronchodilators Bosman, Ingrid Jolanda

Function of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)

Medescan Nebuliser Med - S600A Instructions Manual

History & Development

Significance. Asthma Definition. Focus on Asthma

Effective Date: August 31, 2006 SUBJECT: CARE AND USE OF NEBULIZER AND INTERMITTENT POSITIVE PRESSURE BREATHING DEVICE

It is recommended that a mask and protective eyewear be worn when providing care to a patient with a cough

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Financial Disclosure. Exercise Induced Bronchospasm BHR. Exercise Induced Asthma

Online Data Supplement Effect of CPAP on Airways Reactivity in Asthma: A Randomized Sham-Controlled Clinical Trial

Pulmonary Function Testing

Charles G Irvin PhD and Gregg L Ruppel MEd RRT RPFT FAARC, Section Editors. Conflicting Methacholine Challenge Tests. Jeffrey M Haynes RRT RPFT

Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

ASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides

Benzalkonium Chloride Induced Bronchoconstriction in Patients with Stable Bronchial Asthma

Atrovent Administration

Medications Affecting The Respiratory System

Young Yoo, MD; Jinho Yu, MD; Do Kyun Kim, MD; and Young Yull Koh, MD

Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene

PULMONARY FUNCTION. VOLUMES AND CAPACITIES

RESPIRATORY CARE IN GENERAL PRACTICE

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019

JANUARY Guide to the WADA Prohibited List and Therapeutic Use Exemptions

Spirometric protocol

3. Identify the importance in the prehospital setting for the administration of nebulized bronchodilator.

Your Guide to MANAGING ASTHMA

COMPREHENSIVE RESPIROMETRY

You Take My Breath Away. Student Information Page 5C Part 1

INFORMATION FOR THE CONSUMER IMPORTANT INFORMATION YOU SHOULD KNOW ABOUT

Coexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis

What do pulmonary function tests tell you?

The role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE

Meenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar

PRODUCT MONOGRAPH. 100 mg/vial 480 mg/vial & 1600 mg/vial. Cholinergic / Diagnostic Aid (Bronchial Asthma)

Pulmonary Function Testing. Ramez Sunna MD, FCCP

Subject Index. Carbon monoxide (CO) disease effects on levels 197, 198 measurement in exhaled air 197 sources in exhaled air 197

A step-by-step preparation guide

Respiratory Therapy. Medical/Scientific/General Background

Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma

Presented by UIC College of Nursing

Chronic Obstructive Pulmonary Disease 1/18/2018

Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects

2.0 Scope: This document is to be used by the DCS staff when collecting participants spirometry measurements using the TruFlow Easy-On Spirometer.

Getting Spirometry Right It Matters! Performance, Quality Assessment, and Interpretation. Susan Blonshine RRT, RPFT, AE-C, FAARC

In 2002, it was reported that 72 of 1000

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

West Penn Allegheny Health System Forbes Regional Hospital

Transcription:

powder for solution, for inhalation Performing a Methacholine Challenge Test Provocholine is a registered trademark of Methapharm Inc. Copyright Methapharm Inc. 2016. All rights reserved. Healthcare professionals should consult the Provocholine package insert for the complete product safety information. A sterile 0.22 μm bacterial retentive filter (e.g., Millex GV ) should be used when transferring a solution to the nebulizer. Warning: Provocholine is a bronchoconstrictor agent for diagnostic purposes only and should not be used as a therapeutic agent. Provocholine inhalation challenge should be performed only under the supervision of a physician trained in and thoroughly familiar with all aspects of the technique of methacholine challenge, all contraindications, warnings and precautions, and the management of respiratory distress. Emergency equipment and medication should be immediately available to treat acute respiratory distress. For complete prescribing information, please consult the Product Insert which is available for download at www.provocholine.com or on request by calling Methapharm Medical Information at 1-800-287-7686 +1-519-751-3602 ext 7804 or faxing us at +1-519-751-9149. This information is provided as a professional courtesy, and it is intended to provide data available to us that may assist you in deriving your own conclusions and opinions. This information is not intended to advocate any indications, dosage, or other claim that is not described in the package insert. 1 www.provocholine.com PROVO-PERFORM-R1-0516

Technologist Qualification 1. Be familiar with the guidelines and test procedure. 2. Understand and manage the equipment including set-up, quality control, maintenance, and cleaning. 3. Have established competence with spirometry performance. 4. Know contraindications to methacholine challenge testing (MCT). 5. Be competent to perform emergency procedures and understand the safety procedures. 6. Know when to continue or stop testing. 7. Have established competence in the administration of inhaled bronchodilators and evaluation of the response. 2

Patient Safety 1. A physician or individual qualified to treat acute bronchospasm should be close enough to respond to an emergency. 2. Patients should never be left unattended. 3. Medications to treat severe bronchospasm must be available in the testing room. 4. Oxygen must be available. 5. Additional required equipment includes a nebulizer, stethoscope, sphygmomanometer and pulse oximeter. 3

Technologist Safety 1. Minimize exposure to the methacholine chloride. 2. Consider additional precautions if the technologist has asthma. 4

Overview 1. Pre-Test Provocholine Preparation Equipment Preparation Patient Preparation 2. Test Administration of Provocholine Spirometry Testing 3. Post-Test Return Patient to Baseline Pulmonary Function Evaluate Results 5

1 Provocholine Preparation For instructions on the preparation of the Provocholine solutions for the methacholine challenge test, please view the Mixing Methacholine Dilutions for Bronchoprovocation Challenge Testing video. 6

1 Provocholine Preparation Be sure to remove the Provocholine dilutions from the refrigerator 30 minutes prior to testing to allow it to warm to room temperature. 7

1 Equipment Preparation Nebulizer Spirometer It is important to ensure that you have bronchodilators, oxygen, and emergency equipment available. 8

1 Nebulizer Tidal Breathing Nebulizer must deliver aerosol with particle mass median diameter (MMD) between 1.0 and 3.6 μm Avoid nebulizers with particle MMD < 1.0 μm 9

1 Nebulizer Tidal Breathing Flow meter should be adjusted to deliver an output within 10% of 0.13 ml/minute Nebulizers should be properly calibrated in order to determine the flow meter setting 10

1 Nebulizer Dosimeter Method Flow meter should be adjusted to deliver an output of 0.009 ml + / - 10% of the solution per 0.6 seconds of actuation during inhalation 11

1 Patient Preparation Medication Withholding Contraindications 12

1 Medication Withholding Medication Withholding Time Inhaled agents Short acting bronchodilators 8 hrs Anticholinergenic bronchodilators 24 hrs Long acting bronchodilators 48 hrs Oral Bronchodilators Theophylline 12 hrs Intermediate theophylline 24 hrs Long acting theophyllines 48 hrs Standard Β-agonist 12 hrs Long acting Β-agonist 24 hrs Other Medications Hydroxazine, Cetirazine 3 days Leukotriene modifiers 24 hrs Nedocromil 48 hrs Cromolyn sodium 8 hrs *Crapo R, Casaburi R, Coates A, et al. Guidelines for methacholine and exercise challenge testing - 1999. Am J Respir Crit Care Med 2000 : 161(1):309-29. 13

1 Medication Withholding The ATS does not recommend routinely withholding oral or inhaled corticosteroids, but their anti-inflammatory effect may decrease bronchial responsiveness Antihistamines are generally not withheld 14

1 Medication Withholding Withholding beta-adrenergic blocking agents or performing MCT with these agents should be done with caution and ONLY on specific orders of the ordering physician Crapo R,, et al. Pulmonary Function Laboratory Management and Procedural Manual 2 nd Edition. 2004. 15

1 Contraindications Absolute Relative 16

1 Contraindications - Absolute Known hypersensitivity to methacholine chloride or other parasympathomimetic agents Severe airflow limitation (FEV < 50% predicted 1 or FEV < 1.0 L)* 1 Heart attack (myocardial infarction) or stroke (CVA) within the previous 3 months *Crapo R, Casaburi R, Coates A, et al. Guidelines for methacholine and exercise challenge testing - 1999. Am J Respir Crit Care Med 2000 : 161(1):309-29. 17

1 Contraindications - Absolute Uncontrolled hypertension (systolic BP > 200 and/or diastolic BP > 100 mm Hg) Known arterial aneurysm 18

1 Contraindications - Relative Airflow limitation (reduced FEV /FVC ratio) and 1 FEV < 60% predicted or < 1.5 L* 1 Inability to perform acceptable/repeatable spirometry at baseline Pregnant or nursing mothers Current use of cholinesterase inhibitor medication *Crapo R, Casaburi R, Coates A, et al. Guidelines for methacholine and exercise challenge testing - 1999. Am J Respir Crit Care Med 2000 : 161(1):309-29. 19

1 Contraindications - Relative Significant response to diluent (i.e. FEV falls > 1 10% from baseline after administration of saline solution not containing any methacholine chloride) Upper or lower respiratory-tract infection within previous 2-6 weeks Patients receiving any beta-adrenergic blocking agent 20

1 Patient Preparation Introduce yourself as the patient enters the room. 21

1 Patient Preparation Briefly explain the test that you are about to perform to the patient and any family members who may be present, including the inhalation of the product and the required pulmonary function testing. 22

1 Patient Preparation Encourage the patient to ask any questions he or she may have about the test, and answer those questions in simple words and phrases, avoiding the use of technical terms and acronyms. 23

1 Patient Preparation Confirm patient identification, physician order, clinical history, and indication for testing Assess each patient s ability to perform the MCT Ensure the patient has complied with the preparation criteria including recent illnesses and withholding medications as required 24

1 Baseline Spirometry Perform baseline spirometry according to the most recent ATS/ERS criteria Evaluate the presence of absolute and relative contraindications: If absolute contraindications are present do not proceed with the methacholine challenge test If relative contraindications are present please contact the referring physician 25

2 Administration of Provocholine Tidal Breathing Method Dosimeter Method 26

2 Tidal Breathing Demonstrated with: AeroEclipse II Breath Actuated Nebulizer (BAN) 27

2 Tidal Breathing Dispense the diluent into the nebulizer Attach the nose clip and exhalation filter (Optional) Perform spirometry after inhalation of the diluent is complete 28

2 Tidal Breathing If the highest post-diluent FEV 1 is: > 90% of the highest baseline, empty and clean nebulizer thoroughly, and begin to administer the first dose of Provocholine < 90% and > 80% of the highest baseline, repeat the diluent step < 80% of the highest baseline, contact the ordering physician 29

2 Tidal Breathing Dispense the lowest concentration of Provocholine into the nebulizer Perform spirometry after inhalation of the Provocholine is complete 30

2 Tidal Breathing Repeat the process until either FEV 1 drops at least 20% from the post-diluent baseline or highest concentration has been administered 31

2 Dosimeter Demonstrated with: DeVilbiss model 646 nebulizer 32

2 Dosimeter Dispense the diluent into the nebulizer Attach the nose clip and exhalation filter (Optional) Actuate the dosimeter 2 times to prime the nebulizer and observe adequate nebulization 33

2 Dosimeter Instruct the patient to inhale slowly from Functional Residual Capacity (FRC) to total lung capacity (TLC) and hold the breath at TLC for approximately 5 seconds Alternatively, inhalation to 50-60% of inhalation capacity 34

2 Dosimeter Repeat the maneuver until five breaths have been completed, within 2 minutes Start the timer after the fifth breath has been completed Perform spirometry at 30 and 90 seconds after inhalation of the diluent is complete 35

2 Dosimeter If the highest post-diluent FEV 1 is: > 90% of the highest baseline, empty and clean nebulizer thoroughly, and begin to administer the first dose of Provocholine < 90% and > 80% of the highest baseline, repeat the diluent step < 80% of the highest baseline, contact the ordering physician 36

2 Dosimeter Dispense the lowest concentration of Provocholine into the nebulizer Always prime the dosimeter 2 times Repeat inhalation and spirometric maneuvers 37

2 Dosimeter Repeat the process until either FEV 1 drops at least 20% from the post-diluent baseline or highest concentration has been administered 38

3 Return Patient To Baseline When the FEV is < 80% of the highest postdiluent FEV, administer a bronchodilator 1 1 Wait 10 min and repeat spirometry, ensuring FEV 90% of baseline prior to sending patient 1 home A second bronchodilator may be administered if the FEV < 90% 1 39

3 Reporting Results Primary Outcome: Change in FEV 1 Evaluate the flow volume loop 40

3 Reporting Results Technologist should always include their observations: Did the test meet ATS/ERS criteria for performing an MCT? Why or why not? Any evidence of medication, technique, or history that could impact the reliability of the test results? Were symptoms present? If yes, were the symptoms similar to the initial complaint? 41

3 Reporting Results Include technologist comments concerning cooperation, effort, cough response, wheezing, shortness of breath, or other symptoms 42

3 Reporting Results Present data for each step of the test including the bronchodilator Express each dose in mg/ml For spirometry, report FVC, FEV 1, and the FEV 1 /FVC ratio Express data as percent of baseline or the postdiluent result For plethysmography, report sgaw or sraw 43

3 Reporting Results PC 20 PD 20 PC 40 SG aw 44

3 Reporting Results PC 20 = antilog log C 1 + (log C 2 log C 1 ) (20-R 1 ) R 2 R 1 Where: C 1 = methacholine concentration preceding C 2 C 2 = methacholine concentration causing a 20% drop in FEV 1 from baseline R 1 = percent fall in FEV 1 after C 1 R 2 = percent fall in FEV 1 after C 2 *Crapo R, Casaburi R, Coates A, et al. Guidelines for methacholine and exercise challenge testing - 1999. Am J Respir Crit Care Med 2000 : 161(1):309-29. 45

3 Interpreting Results Categorization of Bronchial Responsiveness (ATS) PC 20 Results Interpretation* >16 mg/ml Normal bronchial responsiveness 4-16 mg/ml Borderline bronchial hyperresponsiveness (BHR) 1-4 mg/ml Mild BHR <1 mg/ml Moderate Severe BHR * This method of interpretation assumes: baseline airway obstruction is absent spirometry quality is good there is substantial post-challenge FEV 1 recovery Crapo R, Casaburi R, Coates A, et al. Guidelines for methacholine and exercise challenge testing - 1999. Am J Respir Crit Care Med 2000 : 161(1):309-29. 46

3 Reporting Results PD 20 = PC 20 x neb output x t Where: PC 20 = Provocative concentration to elicit 20% drop in FEV 1 neb output = flow rate for the nebulizer t = actuation time 47

Summary 1. Pre-Test Provocholine Preparation Equipment Preparation Patient Preparation 2. Test Administration of Provocholine Spirometry Testing 3. Post-Test Return Patient to Baseline Pulmonary Function Evaluate Results 48

Questions or Concerns Contact Methapharm at 1-800-287-7686 49